Introducing the New Semaglutide ELISA Kit (Ozempic®)
Semaglutide has become one of the most extensively studied GLP-1 receptor agonists in diabetes, obesity, and metabolic disease research. As a long-acting analog of glucagon-like peptide-1 (GLP-1), Semaglutide plays a critical role in regulating glycemic control, appetite, and body weight, making it a valuable target for both preclinical and translational studies. It is the active ingredient in widely recognized therapies such as Ozempic® and Wegovy®.
To support researchers investigating GLP-1 biology and peptide therapeutics, BMA Biomedicals offers the Semaglutide ELISA Kit (S-1530), a highly sensitive assay designed for accurate and reproducible quantification of Semaglutide in research samples.
Key Features of the Semaglutide ELISA Kit (S-1530)
✅ Exceptional Sensitivity
Average IC50: 2 ng/mL, allowing reliable detection of low Semaglutide concentrations.
✅ Wide Quantification Range
Detection range of 0-100 ng/mL, suitable for a broad range of pharmacokinetic and biomarker studies.
✅ Research-Grade Specificity
Developed using rabbit antisera generated against Semaglutide, providing high specificity for quantitative analysis.
✅ 96-Well ELISA Format
Convenient kit format providing 96 tests for efficient sample processing and reproducible results.
✅ Optimized for Research Applications
Validated for use with appropriately extracted samples and supplied with a comprehensive assay protocol.
Applications
- GLP-1 receptor agonist research
- Obesity and weight management studies
- Type 2 diabetes research
- Pharmacokinetic and pharmacodynamic analyses
- Drug development and therapeutic monitoring
- Metabolic disease investigations
- Peptide characterization and biomarker discovery
With decades of expertise in peptide immunoassays, BMA Biomedicals delivers trusted ELISA solutions for life science researchers worldwide. The Semaglutide ELISA Kit (S-1530) combines outstanding sensitivity, specificity, and reproducibility to support cutting-edge research in metabolic health and GLP-1 therapeutics.
Be among the first to integrate this essential tool into your research pipeline and contact us at info@bma.ch
We help you keep your research moving forward!
Your BMA team